ID   CALM_HUMAN              Reviewed;         149 AA.
AC   P62158; P02593; P70667; P99014; Q13942; Q53S29; Q61379; Q61380;
AC   Q96HK3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   22-JUL-2015, entry version 153.
DE   RecName: Full=Calmodulin;
DE            Short=CaM;
GN   Name=CALM1; Synonyms=CALM, CAM, CAM1;
GN   and
GN   Name=CALM2; Synonyms=CAM2, CAMB;
GN   and
GN   Name=CALM3; Synonyms=CALML2, CAM3, CAMC, CAMIII;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6385987;
RA   Wawrzynczak E.J., Perham R.N.;
RT   "Isolation and nucleotide sequence of a cDNA encoding human
RT   calmodulin.";
RL   Biochem. Int. 9:177-185(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2445749;
RA   Sengupta B., Friedberg F., Detera-Wadleigh S.D.;
RT   "Molecular analysis of human and rat calmodulin complementary DNA
RT   clones. Evidence for additional active genes in these species.";
RL   J. Biol. Chem. 262:16663-16670(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3182832;
RA   Fischer R., Koller M., Flura M., Mathews S., Strehler-Page M.A.,
RA   Krebs J., Penniston J.T., Carafoli E., Strehler E.E.;
RT   "Multiple divergent mRNAs code for a single human calmodulin.";
RL   J. Biol. Chem. 263:17055-17062(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (CALM3).
RC   TISSUE=Blood;
RX   PubMed=2223880; DOI=10.1016/0167-4781(90)90203-E;
RA   Koller M., Schnyder B., Strehler E.E.;
RT   "Structural organization of the human CaMIII calmodulin gene.";
RL   Biochim. Biophys. Acta 1087:180-189(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (CALM1).
RC   TISSUE=Blood;
RX   PubMed=7925473; DOI=10.1111/j.1432-1033.1994.00071.x;
RA   Rhyner J.A., Ottiger M., Wicki R., Greenwood T.M., Strehler E.E.;
RT   "Structure of the human CALM1 calmodulin gene and identification of
RT   two CALM1-related pseudogenes CALM1P1 and CALM1P2.";
RL   Eur. J. Biochem. 225:71-82(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymphoma;
RA   Kato S.;
RT   "Human calmodulin cDNA.";
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (CALM2).
RX   PubMed=9681195; DOI=10.1016/S0143-4160(98)90028-8;
RA   Toutenhoofd S.L., Foletti D., Wicki R., Rhyner J.A., Garcia F.,
RA   Tolon R., Strehler E.E.;
RT   "Characterization of the human CALM2 calmodulin gene and comparison of
RT   the transcriptional activity of CALM1, CALM2 and CALM3.";
RL   Cell Calcium 23:323-338(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (CALM1; CALM2 AND CALM3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (CALM2).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (CALM1).
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (CALM2).
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (CALM1; CALM2 AND CALM3).
RC   TISSUE=Brain, Lung, Lymph, Placenta, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-149, ACETYLATION AT ALA-2, AND METHYLATION AT
RP   LYS-116.
RC   TISSUE=Brain;
RX   PubMed=7093203; DOI=10.1021/bi00539a041;
RA   Sasagawa T., Ericsson L.H., Walsh K.A., Schreiber W.E., Fischer E.H.,
RA   Titani K.;
RT   "Complete amino acid sequence of human brain calmodulin.";
RL   Biochemistry 21:2565-2569(1982).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-31 AND 92-107, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Bensaad K., Vousden K.H.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 15-31; 77-107 AND 128-149, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   INTERACTION WITH TTN.
RX   PubMed=9804419; DOI=10.1038/27603;
RA   Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O.,
RA   Wilmanns M., Gautel M.;
RT   "Structural basis for activation of the titin kinase domain during
RT   myofibrillogenesis.";
RL   Nature 395:863-869(1998).
RN   [17]
RP   INTERACTION WITH SRY.
RX   PubMed=12871148; DOI=10.2174/0929866033479004;
RA   Kelly S., Yotis J., Macris M., Harley V.;
RT   "Recombinant expression, purification and characterisation of the HMG
RT   domain of human SRY.";
RL   Protein Pept. Lett. 10:281-286(2003).
RN   [18]
RP   INTERACTION WITH USP6.
RX   PubMed=16127172; DOI=10.1074/jbc.M505220200;
RA   Shen C., Ye Y., Robertson S.E., Lau A.W., Mak D.O., Chou M.M.;
RT   "Calcium/calmodulin regulates ubiquitination of the ubiquitin-specific
RT   protease TRE17/USP6.";
RL   J. Biol. Chem. 280:35967-35973(2005).
RN   [19]
RP   INTERACTION WITH SRY.
RX   PubMed=15746192; DOI=10.1210/me.2004-0334;
RA   Sim H., Rimmer K., Kelly S., Ludbrook L.M., Clayton A.H., Harley V.R.;
RT   "Defective calmodulin-mediated nuclear transport of the sex-
RT   determining region of the Y chromosome (SRY) in XY sex reversal.";
RL   Mol. Endocrinol. 19:1884-1892(2005).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [21]
RP   FUNCTION, INTERACTION WITH CCP110, AND SUBCELLULAR LOCATION.
RX   PubMed=16760425; DOI=10.1091/mbc.E06-04-0371;
RA   Tsang W.Y., Spektor A., Luciano D.J., Indjeian V.B., Chen Z.,
RA   Salisbury J.L., Sanchez I., Dynlacht B.D.;
RT   "CP110 cooperates with two calcium-binding proteins to regulate
RT   cytokinesis and genome stability.";
RL   Mol. Biol. Cell 17:3423-3434(2006).
RN   [22]
RP   INTERACTION WITH CEP97 AND CCP110.
RX   PubMed=17719545; DOI=10.1016/j.cell.2007.06.027;
RA   Spektor A., Tsang W.Y., Khoo D., Dynlacht B.D.;
RT   "Cep97 and CP110 suppress a cilia assembly program.";
RL   Cell 130:678-690(2007).
RN   [23]
RP   INTERACTION WITH RYR1 AND RYR2.
RX   PubMed=18650434; DOI=10.1074/jbc.M804432200;
RA   Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F.,
RA   Weber D.J.;
RT   "S100A1 and calmodulin compete for the same binding site on ryanodine
RT   receptor.";
RL   J. Biol. Chem. 283:26676-26683(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-100, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-100 AND TYR-139, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-22 AND LYS-95, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   INTERACTION WITH CDK5RAP2.
RX   PubMed=20466722; DOI=10.1074/jbc.M110.105965;
RA   Wang Z., Wu T., Shi L., Zhang L., Zheng W., Qu J.Y., Niu R., Qi R.Z.;
RT   "Conserved motif of CDK5RAP2 mediates its localization to centrosomes
RT   and the Golgi complex.";
RL   J. Biol. Chem. 285:22658-22665(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [31]
RP   INTERACTION WITH ORAI1.
RX   PubMed=23109337; DOI=10.1074/jbc.M112.380964;
RA   Liu Y., Zheng X., Mueller G.A., Sobhany M., DeRose E.F., Zhang Y.,
RA   London R.E., Birnbaumer L.;
RT   "Crystal structure of calmodulin binding domain of orai1 in complex
RT   with Ca2+ calmodulin displays a unique binding mode.";
RL   J. Biol. Chem. 287:43030-43041(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [33]
RP   INTERACTION WITH FCHO1.
RX   PubMed=22484487; DOI=10.1038/ncb2473;
RA   Umasankar P.K., Sanker S., Thieman J.R., Chakraborty S., Wendland B.,
RA   Tsang M., Traub L.M.;
RT   "Distinct and separable activities of the endocytic clathrin-coat
RT   components Fcho1/2 and AP-2 in developmental patterning.";
RL   Nat. Cell Biol. 14:488-501(2012).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   INVOLVEMENT IN LQT14, VARIANTS LQT14 GLY-130 AND LEU-142,
RP   CHARACTERIZATION OF VARIANTS LQT14 GLY-130 AND LEU-142, INVOLVEMENT IN
RP   LQT15, VARIANT LQT15 VAL-96, AND CHARACTERIZATION OF VARIANT LQT15
RP   VAL-96.
RX   PubMed=23388215; DOI=10.1161/CIRCULATIONAHA.112.001216;
RA   Crotti L., Johnson C.N., Graf E., De Ferrari G.M., Cuneo B.F.,
RA   Ovadia M., Papagiannis J., Feldkamp M.D., Rathi S.G., Kunic J.D.,
RA   Pedrazzini M., Wieland T., Lichtner P., Beckmann B.M., Clark T.,
RA   Shaffer C., Benson D.W., Kaab S., Meitinger T., Strom T.M.,
RA   Chazin W.J., Schwartz P.J., George A.L. Jr.;
RT   "Calmodulin mutations associated with recurrent cardiac arrest in
RT   infants.";
RL   Circulation 127:1009-1017(2013).
RN   [36]
RP   INVOLVEMENT IN LQT15, VARIANTS LQT15 ILE-98; SER-98; GLU-132; HIS-134
RP   AND PRO-136, AND CHARACTERIZATION OF VARIANTS LQT15 ILE-98; GLU-132;
RP   HIS-134 AND PRO-136.
RX   PubMed=24917665; DOI=10.1161/CIRCGENETICS.113.000459;
RA   Makita N., Yagihara N., Crotti L., Johnson C.N., Beckmann B.M.,
RA   Roh M.S., Shigemizu D., Lichtner P., Ishikawa T., Aiba T., Homfray T.,
RA   Behr E.R., Klug D., Denjoy I., Mastantuono E., Theisen D., Tsunoda T.,
RA   Satake W., Toda T., Nakagawa H., Tsuji Y., Tsuchiya T., Yamamoto H.,
RA   Miyamoto Y., Endo N., Kimura A., Ozaki K., Motomura H., Suda K.,
RA   Tanaka T., Schwartz P.J., Meitinger T., Kaeaeb S., Guicheney P.,
RA   Shimizu W., Bhuiyan Z.A., Watanabe H., Chazin W.J., George A.L. Jr.;
RT   "Novel calmodulin mutations associated with congenital arrhythmia
RT   susceptibility.";
RL   Circ. Cardiovasc. Genet. 7:466-474(2014).
RN   [37]
RP   INVOLVEMENT IN LQT14, AND VARIANT LQT14 LEU-90.
RX   PubMed=24076290; DOI=10.1016/j.jacc.2013.07.091;
RA   Marsman R.F., Barc J., Beekman L., Alders M., Dooijes D.,
RA   van den Wijngaard A., Ratbi I., Sefiani A., Bhuiyan Z.A., Wilde A.A.,
RA   Bezzina C.R.;
RT   "A mutation in CALM1 encoding calmodulin in familial idiopathic
RT   ventricular fibrillation in childhood and adolescence.";
RL   J. Am. Coll. Cardiol. 63:259-266(2014).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102 AND THR-111, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   STRUCTURE BY NMR OF 95-104.
RX   PubMed=9927666; DOI=10.1073/pnas.96.3.903;
RA   Siedlecka M., Goch G., Ejchart A., Sticht H., Bierzyski A.;
RT   "Alpha-helix nucleation by a calcium-binding peptide loop.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:903-908(1999).
RN   [40]
RP   STRUCTURE BY NMR OF 1-77 AND 83-149.
RX   PubMed=11685248; DOI=10.1038/nsb1101-990;
RA   Chou J.J., Li S., Klee C.B., Bax A.;
RT   "Solution structure of Ca(2+)-calmodulin reveals flexible hand-like
RT   properties of its domains.";
RL   Nat. Struct. Biol. 8:990-997(2001).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   PubMed=1474585; DOI=10.1016/0022-2836(92)90324-D;
RA   Chattopadhyaya R., Meador W.E., Means A.R., Quiocho F.A.;
RT   "Calmodulin structure refined at 1.7 A resolution.";
RL   J. Mol. Biol. 228:1177-1192(1992).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS).
RX   PubMed=7803388; DOI=10.1021/bi00255a006;
RA   Cook W.J., Walter L.J., Walter M.R.;
RT   "Drug binding by calmodulin: crystal structure of a calmodulin-
RT   trifluoperazine complex.";
RL   Biochemistry 33:15259-15265(1994).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 6-149.
RX   PubMed=11807546; DOI=10.1038/415396a;
RA   Drum C.L., Yan S.-Z., Bard J., Shen Y.-Q., Lu D., Soelaiman S.,
RA   Grabarek Z., Bohm A., Tang W.-J.;
RT   "Structural basis for the activation of anthrax adenylyl cyclase
RT   exotoxin by calmodulin.";
RL   Nature 415:396-402(2002).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (3.6 ANGSTROMS) OF 1-149 IN COMPLEX WITH ANTHRAX
RP   EDEMA FACTOR CYA.
RX   PubMed=12485993; DOI=10.1093/emboj/cdf681;
RA   Shen Y., Lee Y.-S., Soelaiman S., Bergson P., Lu D., Chen A.,
RA   Beckingham K., Grabarek Z., Mrksich M., Tang W.-J.;
RT   "Physiological calcium concentrations regulate calmodulin binding and
RT   catalysis of adenylyl cyclase exotoxins.";
RL   EMBO J. 21:6721-6732(2002).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH MARCKS.
RX   PubMed=12577052; DOI=10.1038/nsb900;
RA   Yamauchi E., Nakatsu T., Matsubara M., Kato H., Taniguchi H.;
RT   "Crystal structure of a MARCKS peptide containing the calmodulin-
RT   binding domain in complex with Ca2+-calmodulin.";
RL   Nat. Struct. Biol. 10:226-231(2003).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-150 IN COMPLEX WITH
RP   CACNA1C.
RX   PubMed=16299511; DOI=10.1038/nsmb1027;
RA   Van Petegem F., Chatelain F.C., Minor D.L. Jr.;
RT   "Insights into voltage-gated calcium channel regulation from the
RT   structure of the CaV1.2 IQ domain-Ca2+/calmodulin complex.";
RL   Nat. Struct. Mol. Biol. 12:1108-1115(2005).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) IN COMPLEX WITH ANTHRAX EDEMA
RP   FACTOR CYA.
RX   PubMed=15719022; DOI=10.1038/sj.emboj.7600574;
RA   Shen Y., Zhukovskaya N.L., Guo Q., Florian J., Tang W.-J.;
RT   "Calcium-independent calmodulin binding and two-metal-ion catalytic
RT   mechanism of anthrax edema factor.";
RL   EMBO J. 24:929-941(2005).
RN   [48]
RP   STRUCTURE BY NMR IN COMPLEX WITH SCN5A.
RX   PubMed=21167176; DOI=10.1016/j.jmb.2010.11.046;
RA   Chagot B., Chazin W.J.;
RT   "Solution NMR structure of Apo-calmodulin in complex with the IQ motif
RT   of human cardiac sodium channel NaV1.5.";
RL   J. Mol. Biol. 406:106-119(2011).
RN   [49]
RP   STRUCTURE BY ELECTRON MICROSCOPY (25 ANGSTROMS) IN COMPLEX WITH MIP,
RP   FUNCTION, AND INTERACTION WITH MIP.
RX   PubMed=23893133; DOI=10.1038/nsmb.2630;
RA   Reichow S.L., Clemens D.M., Freites J.A., Nemeth-Cahalan K.L.,
RA   Heyden M., Tobias D.J., Hall J.E., Gonen T.;
RT   "Allosteric mechanism of water-channel gating by Ca(2+)-calmodulin.";
RL   Nat. Struct. Mol. Biol. 20:1085-1092(2013).
RN   [50]
RP   VARIANTS CPVT4 ILE-54 AND SER-98, AND CHARACTERIZATION OF VARIANTS
RP   CPVT4 ILE-54 AND SER-98.
RX   PubMed=23040497; DOI=10.1016/j.ajhg.2012.08.015;
RA   Nyegaard M., Overgaard M.T., Sondergaard M.T., Vranas M., Behr E.R.,
RA   Hildebrandt L.L., Lund J., Hedley P.L., Camm A.J., Wettrell G.,
RA   Fosdal I., Christiansen M., Borglum A.D.;
RT   "Mutations in calmodulin cause ventricular tachycardia and sudden
RT   cardiac death.";
RL   Am. J. Hum. Genet. 91:703-712(2012).
CC   -!- FUNCTION: Calmodulin mediates the control of a large number of
CC       enzymes, ion channels, aquaporins and other proteins by Ca(2+).
CC       Among the enzymes to be stimulated by the calmodulin-Ca(2+)
CC       complex are a number of protein kinases and phosphatases. Together
CC       with CCP110 and centrin, is involved in a genetic pathway that
CC       regulates the centrosome cycle and progression through
CC       cytokinesis. {ECO:0000269|PubMed:16760425,
CC       ECO:0000269|PubMed:23893133}.
CC   -!- SUBUNIT: Interacts with MYO1C, MYO5A and RRAD. Interacts with
CC       MYO10 (By similarity). Interacts with CEP97, CCP110, TTN/titin and
CC       SRY. Interacts with USP6; the interaction is calcium dependent.
CC       Interacts with CDK5RAP2. Interacts with SCN5A. Interacts with RYR1
CC       and RYR2. Interacts with FCHO1. Interacts with MIP in a 1:2
CC       stoichiometry; the interaction with the cytoplasmic domains from
CC       two MIP subunits promotes MIP water channel closure. Interacts
CC       with ORAI1; this may play a role in the regulation of ORAI1-
CC       mediated calcium transport. {ECO:0000250,
CC       ECO:0000269|PubMed:12485993, ECO:0000269|PubMed:12577052,
CC       ECO:0000269|PubMed:12871148, ECO:0000269|PubMed:15719022,
CC       ECO:0000269|PubMed:15746192, ECO:0000269|PubMed:16127172,
CC       ECO:0000269|PubMed:16299511, ECO:0000269|PubMed:16760425,
CC       ECO:0000269|PubMed:17719545, ECO:0000269|PubMed:18650434,
CC       ECO:0000269|PubMed:20466722, ECO:0000269|PubMed:21167176,
CC       ECO:0000269|PubMed:22484487, ECO:0000269|PubMed:23109337,
CC       ECO:0000269|PubMed:23893133, ECO:0000269|PubMed:9804419}.
CC   -!- INTERACTION:
CC       Q9Z305:- (xeno); NbExp=2; IntAct=EBI-397435, EBI-9084208;
CC       P29274:ADORA2A; NbExp=3; IntAct=EBI-397435, EBI-2902702;
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-397435, EBI-743313;
CC       P32121:ARRB2; NbExp=3; IntAct=EBI-397435, EBI-714559;
CC       Q8NCR3:C11orf65; NbExp=3; IntAct=EBI-397435, EBI-744790;
CC       Q13936:CACNA1C; NbExp=12; IntAct=EBI-397435, EBI-1038838;
CC       O43303:CCP110; NbExp=9; IntAct=EBI-397435, EBI-1566217;
CC       P40136:cya (xeno); NbExp=8; IntAct=EBI-397435, EBI-457011;
CC       P53355:DAPK1; NbExp=6; IntAct=EBI-397435, EBI-358616;
CC       P00533:EGFR; NbExp=4; IntAct=EBI-397435, EBI-297353;
CC       P25445:FAS; NbExp=4; IntAct=EBI-397435, EBI-494743;
CC       O95259:KCNH1; NbExp=4; IntAct=EBI-397435, EBI-2909270;
CC       O95259-2:KCNH1; NbExp=8; IntAct=EBI-397435, EBI-9836801;
CC       A0JP07:KIAA1683; NbExp=3; IntAct=EBI-397435, EBI-10171456;
CC       Q9H0B3:KIAA1683; NbExp=4; IntAct=EBI-397435, EBI-745878;
CC       P26645:Marcks (xeno); NbExp=2; IntAct=EBI-397435, EBI-911805;
CC       Q9HD67:MYO10; NbExp=2; IntAct=EBI-397435, EBI-307061;
CC       Q96PM5:RCHY1; NbExp=2; IntAct=EBI-397435, EBI-947779;
CC       Q14524:SCN5A; NbExp=2; IntAct=EBI-397435, EBI-726858;
CC       Q8WZ42:TTN; NbExp=2; IntAct=EBI-397435, EBI-681210;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-397435, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:16760425}. Cytoplasm, cytoskeleton, spindle
CC       pole {ECO:0000269|PubMed:16760425}. Note=Distributed throughout
CC       the cell during interphase, but during mitosis becomes
CC       dramatically localized to the spindle poles and the spindle
CC       microtubules.
CC   -!- PTM: Ubiquitination results in a strongly decreased activity.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation results in a decreased activity.
CC       {ECO:0000250}.
CC   -!- DISEASE: Ventricular tachycardia, catecholaminergic polymorphic, 4
CC       (CPVT4) [MIM:614916]: An arrhythmogenic disorder characterized by
CC       stress-induced, bidirectional ventricular tachycardia that may
CC       degenerate into cardiac arrest and cause sudden death. Patients
CC       present with recurrent syncope, seizures, or sudden death after
CC       physical activity or emotional stress.
CC       {ECO:0000269|PubMed:23040497}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Long QT syndrome 14 (LQT14) [MIM:616247]: A form of long
CC       QT syndrome, a heart disorder characterized by a prolonged QT
CC       interval on the ECG and polymorphic ventricular arrhythmias. They
CC       cause syncope and sudden death in response to exercise or
CC       emotional stress, and can present with a sentinel event of sudden
CC       cardiac death in infancy. {ECO:0000269|PubMed:23388215,
CC       ECO:0000269|PubMed:24076290}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Long QT syndrome 15 (LQT15) [MIM:616249]: A form of long
CC       QT syndrome, a heart disorder characterized by a prolonged QT
CC       interval on the ECG and polymorphic ventricular arrhythmias. They
CC       cause syncope and sudden death in response to exercise or
CC       emotional stress, and can present with a sentinel event of sudden
CC       cardiac death in infancy. {ECO:0000269|PubMed:23388215,
CC       ECO:0000269|PubMed:24917665}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: This protein has four functional calcium-binding
CC       sites.
CC   -!- SIMILARITY: Belongs to the calmodulin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EF-hand domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00448}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA36839.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=A question of length -
CC       Issue 105 of May 2009;
CC       URL="http://web.expasy.org/spotlight/back_issues/105";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04046; AAA51918.1; -; mRNA.
DR   EMBL; M19311; AAA35641.1; -; mRNA.
DR   EMBL; M27319; AAA35635.1; -; mRNA.
DR   EMBL; X52606; CAA36839.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X52607; CAA36839.1; JOINED; Genomic_DNA.
DR   EMBL; X52608; CAA36839.1; JOINED; Genomic_DNA.
DR   EMBL; U12022; AAB60644.1; -; Genomic_DNA.
DR   EMBL; U11886; AAB60644.1; JOINED; Genomic_DNA.
DR   EMBL; D45887; BAA08302.1; -; mRNA.
DR   EMBL; U94728; AAC83174.1; -; Genomic_DNA.
DR   EMBL; U94725; AAC83174.1; JOINED; Genomic_DNA.
DR   EMBL; U94726; AAC83174.1; JOINED; Genomic_DNA.
DR   EMBL; BT006818; AAP35464.1; -; mRNA.
DR   EMBL; BT006855; AAP35501.1; -; mRNA.
DR   EMBL; BT009916; AAP88918.1; -; mRNA.
DR   EMBL; CR541990; CAG46787.1; -; mRNA.
DR   EMBL; CR542021; CAG46818.1; -; mRNA.
DR   EMBL; AC006536; AAD45181.1; -; Genomic_DNA.
DR   EMBL; AC073283; AAY24085.1; -; Genomic_DNA.
DR   EMBL; BC000454; AAH00454.1; -; mRNA.
DR   EMBL; BC003354; AAH03354.1; -; mRNA.
DR   EMBL; BC005137; AAH05137.1; -; mRNA.
DR   EMBL; BC006464; AAH06464.1; -; mRNA.
DR   EMBL; BC008437; AAH08437.1; -; mRNA.
DR   EMBL; BC008597; AAH08597.1; -; mRNA.
DR   EMBL; BC011834; AAH11834.1; -; mRNA.
DR   EMBL; BC017385; AAH17385.1; -; mRNA.
DR   EMBL; BC018677; AAH18677.1; -; mRNA.
DR   EMBL; BC026065; AAH26065.1; -; mRNA.
DR   EMBL; BC047523; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS1832.1; -.
DR   CCDS; CCDS33061.1; -.
DR   CCDS; CCDS9892.1; -.
DR   PIR; S48728; MCHU.
DR   RefSeq; NP_001292553.1; NM_001305624.1.
DR   RefSeq; NP_001292554.1; NM_001305625.1.
DR   RefSeq; NP_001292555.1; NM_001305626.1.
DR   RefSeq; NP_001734.1; NM_001743.5.
DR   RefSeq; NP_005175.2; NM_005184.2.
DR   RefSeq; NP_008819.1; NM_006888.4.
DR   UniGene; Hs.282410; -.
DR   UniGene; Hs.468442; -.
DR   UniGene; Hs.515487; -.
DR   PDB; 1AJI; Model; -; A=5-148.
DR   PDB; 1CDL; X-ray; 2.00 A; A/B/C/D=2-148.
DR   PDB; 1CLL; X-ray; 1.70 A; A=2-149.
DR   PDB; 1CTR; X-ray; 2.45 A; A=2-149.
DR   PDB; 1IWQ; X-ray; 2.00 A; A=2-149.
DR   PDB; 1J7O; NMR; -; A=2-77.
DR   PDB; 1J7P; NMR; -; A=83-149.
DR   PDB; 1K90; X-ray; 2.75 A; D/E/F=2-149.
DR   PDB; 1K93; X-ray; 2.95 A; D/E/F=6-149.
DR   PDB; 1L7Z; X-ray; 2.30 A; A=2-149.
DR   PDB; 1LVC; X-ray; 3.60 A; D/E/F=1-149.
DR   PDB; 1NKF; NMR; -; A=94-105.
DR   PDB; 1PK0; X-ray; 3.30 A; D/E/F=2-148.
DR   PDB; 1S26; X-ray; 3.00 A; D/E/F=2-149.
DR   PDB; 1SK6; X-ray; 3.20 A; D/E/F=2-149.
DR   PDB; 1SW8; NMR; -; A=2-80.
DR   PDB; 1WRZ; X-ray; 2.00 A; A=1-149.
DR   PDB; 1XFU; X-ray; 3.35 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1XFV; X-ray; 3.35 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1XFW; X-ray; 3.40 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1XFX; X-ray; 3.20 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1XFY; X-ray; 3.30 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1XFZ; X-ray; 3.25 A; O/P/Q/R/S/T=1-149.
DR   PDB; 1Y6W; X-ray; 2.40 A; A=2-149.
DR   PDB; 1YR5; X-ray; 1.70 A; A=2-149.
DR   PDB; 1YRT; X-ray; 2.10 A; B=76-149.
DR   PDB; 1YRU; X-ray; 2.50 A; B=76-149.
DR   PDB; 1ZOT; X-ray; 2.20 A; B=80-148.
DR   PDB; 1ZUZ; X-ray; 1.91 A; A=1-149.
DR   PDB; 2BE6; X-ray; 2.00 A; A/B/C=1-149.
DR   PDB; 2F3Y; X-ray; 1.45 A; A=2-149.
DR   PDB; 2F3Z; X-ray; 1.60 A; A=2-149.
DR   PDB; 2HF5; NMR; -; A=47-113.
DR   PDB; 2I08; X-ray; 2.00 A; A=3-79.
DR   PDB; 2JZI; NMR; -; A=2-149.
DR   PDB; 2K0E; NMR; -; A=2-149.
DR   PDB; 2K0F; NMR; -; A=2-149.
DR   PDB; 2K0J; NMR; -; A=3-149.
DR   PDB; 2K61; NMR; -; A=2-149.
DR   PDB; 2KNE; NMR; -; A=2-149.
DR   PDB; 2KUG; NMR; -; A=2-77.
DR   PDB; 2KUH; NMR; -; A=83-149.
DR   PDB; 2L53; NMR; -; A=2-149.
DR   PDB; 2L7L; NMR; -; A=2-149.
DR   PDB; 2LGF; NMR; -; A=4-149.
DR   PDB; 2LL6; NMR; -; A=2-149.
DR   PDB; 2LL7; NMR; -; A=2-149.
DR   PDB; 2LQC; NMR; -; A=2-78.
DR   PDB; 2LQP; NMR; -; A=79-149.
DR   PDB; 2LV6; Other; -; A=2-149.
DR   PDB; 2M0J; NMR; -; A=2-149.
DR   PDB; 2M0K; NMR; -; A=2-149.
DR   PDB; 2M55; NMR; -; A=2-149.
DR   PDB; 2MG5; NMR; -; A=2-149.
DR   PDB; 2R28; X-ray; 1.86 A; A/B=1-149.
DR   PDB; 2V01; X-ray; 2.15 A; A=2-149.
DR   PDB; 2V02; X-ray; 2.20 A; A=2-149.
DR   PDB; 2VAY; X-ray; 1.94 A; A=4-149.
DR   PDB; 2W73; X-ray; 1.45 A; A/B/E/F=1-149.
DR   PDB; 2WEL; X-ray; 1.90 A; D=1-149.
DR   PDB; 2X0G; X-ray; 2.20 A; B=2-149.
DR   PDB; 2Y4V; X-ray; 1.80 A; A=1-149.
DR   PDB; 3BYA; X-ray; 1.85 A; A=2-149.
DR   PDB; 3DVE; X-ray; 2.35 A; A=2-149.
DR   PDB; 3DVJ; X-ray; 2.80 A; A=2-149.
DR   PDB; 3DVK; X-ray; 2.30 A; A=2-149.
DR   PDB; 3DVM; X-ray; 2.60 A; A=2-149.
DR   PDB; 3EWT; X-ray; 2.40 A; A=2-149.
DR   PDB; 3EWV; X-ray; 2.60 A; A=2-149.
DR   PDB; 3G43; X-ray; 2.10 A; A/B/C/D=2-149.
DR   PDB; 3HR4; X-ray; 2.50 A; B/D/F/H=1-149.
DR   PDB; 3J41; EM; 25.0 A; E/F=1-149.
DR   PDB; 3O77; X-ray; 2.35 A; A=1-149.
DR   PDB; 3O78; X-ray; 2.60 A; A/B=3-149.
DR   PDB; 3OXQ; X-ray; 2.55 A; A/B/C/D=1-149.
DR   PDB; 3SUI; X-ray; 1.95 A; A=1-149.
DR   PDB; 3UCT; X-ray; 1.90 A; A/B=2-80.
DR   PDB; 3UCW; X-ray; 1.76 A; A/B/C/D=2-80.
DR   PDB; 3UCY; X-ray; 1.80 A; A=2-80.
DR   PDB; 4BW7; X-ray; 1.81 A; A/C=1-149.
DR   PDB; 4BW8; X-ray; 1.80 A; A/B=1-149.
DR   PDB; 4BYF; X-ray; 2.74 A; B/D=1-149.
DR   PDB; 4DCK; X-ray; 2.20 A; B=1-149.
DR   PDB; 4DJC; X-ray; 1.35 A; A=1-149.
DR   PDB; 4GOW; X-ray; 2.60 A; D=4-147.
DR   PDB; 4JPZ; X-ray; 3.02 A; C/I=1-149.
DR   PDB; 4JQ0; X-ray; 3.84 A; C=1-149.
DR   PDB; 4L79; X-ray; 2.30 A; B=1-149.
DR   PDB; 4LZX; X-ray; 1.50 A; A=2-149.
DR   PDB; 4M1L; X-ray; 2.10 A; A=2-149.
DR   PDB; 4OVN; X-ray; 2.80 A; A/B/C/D/E=1-149.
DR   PDB; 4Q57; X-ray; 1.80 A; A=10-74.
DR   PDB; 4Q5U; X-ray; 1.95 A; A=1-149.
DR   PDB; 4UMO; X-ray; 3.00 A; C/D=1-149.
DR   PDB; 4UPU; X-ray; 2.34 A; A=2-149.
DR   PDB; 4V0C; X-ray; 2.86 A; C/D=1-149.
DR   PDBsum; 1AJI; -.
DR   PDBsum; 1CDL; -.
DR   PDBsum; 1CLL; -.
DR   PDBsum; 1CTR; -.
DR   PDBsum; 1IWQ; -.
DR   PDBsum; 1J7O; -.
DR   PDBsum; 1J7P; -.
DR   PDBsum; 1K90; -.
DR   PDBsum; 1K93; -.
DR   PDBsum; 1L7Z; -.
DR   PDBsum; 1LVC; -.
DR   PDBsum; 1NKF; -.
DR   PDBsum; 1PK0; -.
DR   PDBsum; 1S26; -.
DR   PDBsum; 1SK6; -.
DR   PDBsum; 1SW8; -.
DR   PDBsum; 1WRZ; -.
DR   PDBsum; 1XFU; -.
DR   PDBsum; 1XFV; -.
DR   PDBsum; 1XFW; -.
DR   PDBsum; 1XFX; -.
DR   PDBsum; 1XFY; -.
DR   PDBsum; 1XFZ; -.
DR   PDBsum; 1Y6W; -.
DR   PDBsum; 1YR5; -.
DR   PDBsum; 1YRT; -.
DR   PDBsum; 1YRU; -.
DR   PDBsum; 1ZOT; -.
DR   PDBsum; 1ZUZ; -.
DR   PDBsum; 2BE6; -.
DR   PDBsum; 2F3Y; -.
DR   PDBsum; 2F3Z; -.
DR   PDBsum; 2HF5; -.
DR   PDBsum; 2I08; -.
DR   PDBsum; 2JZI; -.
DR   PDBsum; 2K0E; -.
DR   PDBsum; 2K0F; -.
DR   PDBsum; 2K0J; -.
DR   PDBsum; 2K61; -.
DR   PDBsum; 2KNE; -.
DR   PDBsum; 2KUG; -.
DR   PDBsum; 2KUH; -.
DR   PDBsum; 2L53; -.
DR   PDBsum; 2L7L; -.
DR   PDBsum; 2LGF; -.
DR   PDBsum; 2LL6; -.
DR   PDBsum; 2LL7; -.
DR   PDBsum; 2LQC; -.
DR   PDBsum; 2LQP; -.
DR   PDBsum; 2LV6; -.
DR   PDBsum; 2M0J; -.
DR   PDBsum; 2M0K; -.
DR   PDBsum; 2M55; -.
DR   PDBsum; 2MG5; -.
DR   PDBsum; 2R28; -.
DR   PDBsum; 2V01; -.
DR   PDBsum; 2V02; -.
DR   PDBsum; 2VAY; -.
DR   PDBsum; 2W73; -.
DR   PDBsum; 2WEL; -.
DR   PDBsum; 2X0G; -.
DR   PDBsum; 2Y4V; -.
DR   PDBsum; 3BYA; -.
DR   PDBsum; 3DVE; -.
DR   PDBsum; 3DVJ; -.
DR   PDBsum; 3DVK; -.
DR   PDBsum; 3DVM; -.
DR   PDBsum; 3EWT; -.
DR   PDBsum; 3EWV; -.
DR   PDBsum; 3G43; -.
DR   PDBsum; 3HR4; -.
DR   PDBsum; 3J41; -.
DR   PDBsum; 3O77; -.
DR   PDBsum; 3O78; -.
DR   PDBsum; 3OXQ; -.
DR   PDBsum; 3SUI; -.
DR   PDBsum; 3UCT; -.
DR   PDBsum; 3UCW; -.
DR   PDBsum; 3UCY; -.
DR   PDBsum; 4BW7; -.
DR   PDBsum; 4BW8; -.
DR   PDBsum; 4BYF; -.
DR   PDBsum; 4DCK; -.
DR   PDBsum; 4DJC; -.
DR   PDBsum; 4GOW; -.
DR   PDBsum; 4JPZ; -.
DR   PDBsum; 4JQ0; -.
DR   PDBsum; 4L79; -.
DR   PDBsum; 4LZX; -.
DR   PDBsum; 4M1L; -.
DR   PDBsum; 4OVN; -.
DR   PDBsum; 4Q57; -.
DR   PDBsum; 4Q5U; -.
DR   PDBsum; 4UMO; -.
DR   PDBsum; 4UPU; -.
DR   PDBsum; 4V0C; -.
DR   ProteinModelPortal; P62158; -.
DR   SMR; P62158; 1-149.
DR   BioGrid; 107252; 371.
DR   BioGrid; 107256; 29.
DR   BioGrid; 107259; 30.
DR   DIP; DIP-31794N; -.
DR   IntAct; P62158; 201.
DR   MINT; MINT-4999725; -.
DR   STRING; 9606.ENSP00000349467; -.
DR   BindingDB; P62158; -.
DR   ChEMBL; CHEMBL6093; -.
DR   DrugBank; DB01429; Aprindine.
DR   DrugBank; DB01244; Bepridil.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00527; Cinchocaine.
DR   DrugBank; DB01023; Felodipine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB00850; Perphenazine.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB01100; Pimozide.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00831; Trifluoperazine.
DR   TCDB; 9.C.15.1.1; the animal calmodulin-dependent e.r. secretion pathway (csp) family.
DR   PhosphoSite; P62158; -.
DR   BioMuta; CALM1; -.
DR   DMDM; 49037474; -.
DR   DOSAC-COBS-2DPAGE; P62158; -.
DR   OGP; P02593; -.
DR   SWISS-2DPAGE; P62158; -.
DR   MaxQB; P62158; -.
DR   PaxDb; P62158; -.
DR   PRIDE; P62158; -.
DR   DNASU; 801; -.
DR   DNASU; 805; -.
DR   DNASU; 808; -.
DR   Ensembl; ENST00000272298; ENSP00000272298; ENSG00000143933.
DR   Ensembl; ENST00000291295; ENSP00000291295; ENSG00000160014.
DR   Ensembl; ENST00000356978; ENSP00000349467; ENSG00000198668.
DR   Ensembl; ENST00000596362; ENSP00000472141; ENSG00000160014.
DR   GeneID; 801; -.
DR   GeneID; 805; -.
DR   GeneID; 808; -.
DR   KEGG; hsa:801; -.
DR   KEGG; hsa:805; -.
DR   KEGG; hsa:808; -.
DR   UCSC; uc001xyl.2; human.
DR   CTD; 801; -.
DR   CTD; 805; -.
DR   CTD; 808; -.
DR   GeneCards; GC02M047387; -.
DR   GeneCards; GC14P090863; -.
DR   GeneCards; GC19P047105; -.
DR   GeneReviews; CALM1; -.
DR   HGNC; HGNC:1442; CALM1.
DR   HGNC; HGNC:1445; CALM2.
DR   HGNC; HGNC:1449; CALM3.
DR   HPA; CAB007790; -.
DR   HPA; CAB018558; -.
DR   HPA; HPA044999; -.
DR   MIM; 114180; gene.
DR   MIM; 114182; gene.
DR   MIM; 114183; gene.
DR   MIM; 614916; phenotype.
DR   MIM; 616247; phenotype.
DR   MIM; 616249; phenotype.
DR   neXtProt; NX_P62158; -.
DR   Orphanet; 3286; Catecholaminergic polymorphic ventricular tachycardia.
DR   PharmGKB; PA26042; -.
DR   eggNOG; COG5126; -.
DR   GeneTree; ENSGT00760000118901; -.
DR   HOVERGEN; HBG012180; -.
DR   InParanoid; P62158; -.
DR   KO; K02183; -.
DR   OMA; HRISGKA; -.
DR   PhylomeDB; P62158; -.
DR   TreeFam; TF300912; -.
DR   BioCyc; MetaCyc:ENSG00000143933-MONOMER; -.
DR   Reactome; REACT_1008; Glycogen breakdown (glycogenolysis).
DR   Reactome; REACT_111176; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; REACT_118700; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   Reactome; REACT_12477; eNOS activation.
DR   Reactome; REACT_147867; Translocation of GLUT4 to the plasma membrane.
DR   Reactome; REACT_150312; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; REACT_15334; DARPP-32 events.
DR   Reactome; REACT_15408; Cam-PDE 1 activation.
DR   Reactome; REACT_15502; CaMK IV-mediated phosphorylation of CREB.
DR   Reactome; REACT_163834; FCERI mediated Ca+2 mobilization.
DR   Reactome; REACT_163919; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; REACT_188329; CLEC7A (Dectin-1) induces NFAT activation.
DR   Reactome; REACT_20546; Ras activation uopn Ca2+ infux through NMDA receptor.
DR   Reactome; REACT_20558; Smooth Muscle Contraction.
DR   Reactome; REACT_20642; CREB phosphorylation through the activation of CaMKII.
DR   Reactome; REACT_20652; Activation of CaMK IV.
DR   Reactome; REACT_20661; CREB phosphorylation through the activation of CaMKK.
DR   Reactome; REACT_21346; Activation of Ca-permeable Kainate Receptor.
DR   Reactome; REACT_263982; Ca2+ pathway.
DR   Reactome; REACT_263991; VEGFR2 mediated vascular permeability.
DR   Reactome; REACT_264273; VEGFR2 mediated cell proliferation.
DR   Reactome; REACT_318; Platelet degranulation.
DR   Reactome; REACT_355347; RHO GTPases activate PAKs.
DR   Reactome; REACT_355469; RHO GTPases activate IQGAPs.
DR   Reactome; REACT_9000; Calmodulin induced events.
DR   Reactome; REACT_9053; CaM pathway.
DR   ChiTaRS; CALM1; human.
DR   ChiTaRS; CALM3; human.
DR   EvolutionaryTrace; P62158; -.
DR   GeneWiki; CALM2; -.
DR   GeneWiki; CALM3; -.
DR   GeneWiki; Calmodulin_1; -.
DR   NextBio; 3264; -.
DR   PRO; PR:P62158; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P62158; -.
DR   CleanEx; HS_CALM1; -.
DR   CleanEx; HS_CALM2; -.
DR   ExpressionAtlas; P62158; baseline and differential.
DR   Genevisible; P62158; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:UniProtKB.
DR   GO; GO:0030017; C:sarcomere; IDA:BHF-UCL.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0031997; F:N-terminal myristoylation domain binding; IPI:UniProtKB.
DR   GO; GO:0043274; F:phospholipase binding; IPI:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0072542; F:protein phosphatase activator activity; IDA:BHF-UCL.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; TAS:BHF-UCL.
DR   GO; GO:0031996; F:thioesterase binding; IPI:UniProtKB.
DR   GO; GO:0031432; F:titin binding; IPI:BHF-UCL.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0005513; P:detection of calcium ion; IMP:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:Reactome.
DR   GO; GO:0005980; P:glycogen catabolic process; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006936; P:muscle contraction; TAS:Reactome.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0060315; P:negative regulation of ryanodine-sensitive calcium-release channel activity; ISS:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046209; P:nitric oxide metabolic process; TAS:Reactome.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0030801; P:positive regulation of cyclic nucleotide metabolic process; IDA:BHF-UCL.
DR   GO; GO:0051343; P:positive regulation of cyclic-nucleotide phosphodiesterase activity; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; TAS:BHF-UCL.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; TAS:BHF-UCL.
DR   GO; GO:0060316; P:positive regulation of ryanodine-sensitive calcium-release channel activity; IDA:BHF-UCL.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; IC:BHF-UCL.
DR   GO; GO:1901844; P:regulation of cell communication by electrical coupling involved in cardiac conduction; IC:BHF-UCL.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; TAS:Reactome.
DR   GO; GO:0010880; P:regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0022400; P:regulation of rhodopsin mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0016056; P:rhodopsin mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 1.10.238.10; -; 2.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   Pfam; PF13499; EF-hand_7; 2.
DR   SMART; SM00054; EFh; 4.
DR   PROSITE; PS00018; EF_HAND_1; 4.
DR   PROSITE; PS50222; EF_HAND_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Calcium; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Isopeptide bond; Long QT syndrome; Metal-binding; Methylation;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|PubMed:22814378,
FT                                ECO:0000269|PubMed:7093203,
FT                                ECO:0000269|Ref.14}.
FT   CHAIN         2    149       Calmodulin.
FT                                /FTId=PRO_0000198223.
FT   DOMAIN        8     43       EF-hand 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN       44     79       EF-hand 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN       81    116       EF-hand 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      117    149       EF-hand 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND      21     32       1.
FT   CA_BIND      57     68       2.
FT   CA_BIND      94    105       3.
FT   CA_BIND     130    141       4.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|PubMed:22814378,
FT                                ECO:0000269|PubMed:7093203,
FT                                ECO:0000269|Ref.14}.
FT   MOD_RES      22     22       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES      45     45       Phosphothreonine; by CaMK4.
FT                                {ECO:0000250}.
FT   MOD_RES      95     95       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     100    100       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     102    102       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     111    111       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     116    116       N6,N6,N6-trimethyllysine.
FT                                {ECO:0000269|PubMed:7093203}.
FT   MOD_RES     139    139       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   CROSSLNK     22     22       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000250}.
FT   VARIANT      54     54       N -> I (in CPVT4; the mutant has
FT                                significantly reduced Ca(2+) affinity
FT                                compared to wild-type).
FT                                {ECO:0000269|PubMed:23040497}.
FT                                /FTId=VAR_069222.
FT   VARIANT      73     73       M -> T (in dbSNP:rs41389749).
FT                                /FTId=VAR_048585.
FT   VARIANT      90     90       F -> L (in LQT14).
FT                                {ECO:0000269|PubMed:24076290}.
FT                                /FTId=VAR_073275.
FT   VARIANT      96     96       D -> V (in LQT15; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:23388215}.
FT                                /FTId=VAR_073276.
FT   VARIANT      98     98       N -> I (in LQT15; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:24917665}.
FT                                /FTId=VAR_073277.
FT   VARIANT      98     98       N -> S (in CPVT4 and LQT15; the mutant
FT                                has significantly reduced Ca(2+) affinity
FT                                compared to wild-type; calmodulin-RYR2
FT                                interaction is defective at low
FT                                intracellular Ca(2+) concentrations and
FT                                restored at moderate to high Ca(2+)
FT                                concentrations).
FT                                {ECO:0000269|PubMed:23040497,
FT                                ECO:0000269|PubMed:24917665}.
FT                                /FTId=VAR_069223.
FT   VARIANT     130    130       D -> G (in LQT14; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:23388215}.
FT                                /FTId=VAR_073278.
FT   VARIANT     132    132       D -> E (in LQT15; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:24917665}.
FT                                /FTId=VAR_073279.
FT   VARIANT     134    134       D -> H (in LQT15; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:24917665}.
FT                                /FTId=VAR_073280.
FT   VARIANT     136    136       Q -> P (in LQT15; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:24917665}.
FT                                /FTId=VAR_073281.
FT   VARIANT     142    142       F -> L (in LQT14; reduction in Ca(2+)
FT                                affinity). {ECO:0000269|PubMed:23388215}.
FT                                /FTId=VAR_073282.
FT   CONFLICT    124    124       E -> Q (in Ref. 12; AAH08437).
FT                                {ECO:0000305}.
FT   HELIX         2      4       {ECO:0000244|PDB:4DJC}.
FT   HELIX         7     20       {ECO:0000244|PDB:4DJC}.
FT   STRAND       21     23       {ECO:0000244|PDB:2M0J}.
FT   STRAND       25     28       {ECO:0000244|PDB:4DJC}.
FT   HELIX        30     39       {ECO:0000244|PDB:4DJC}.
FT   HELIX        46     56       {ECO:0000244|PDB:4DJC}.
FT   HELIX        57     59       {ECO:0000244|PDB:4LZX}.
FT   STRAND       61     65       {ECO:0000244|PDB:4DJC}.
FT   HELIX        66     93       {ECO:0000244|PDB:4DJC}.
FT   STRAND       94     96       {ECO:0000244|PDB:1WRZ}.
FT   STRAND       97    101       {ECO:0000244|PDB:4DJC}.
FT   HELIX       103    112       {ECO:0000244|PDB:4DJC}.
FT   STRAND      113    115       {ECO:0000244|PDB:4LZX}.
FT   HELIX       119    129       {ECO:0000244|PDB:4DJC}.
FT   TURN        130    132       {ECO:0000244|PDB:4DCK}.
FT   STRAND      133    138       {ECO:0000244|PDB:4DJC}.
FT   HELIX       139    146       {ECO:0000244|PDB:4DJC}.
SQ   SEQUENCE   149 AA;  16838 MW;  6B4BC3FCDE10727B CRC64;
     MADQLTEEQI AEFKEAFSLF DKDGDGTITT KELGTVMRSL GQNPTEAELQ DMINEVDADG
     NGTIDFPEFL TMMARKMKDT DSEEEIREAF RVFDKDGNGY ISAAELRHVM TNLGEKLTDE
     EVDEMIREAD IDGDGQVNYE EFVQMMTAK
//
